{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:49:03Z","timestamp":1761756543656,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001415"],"award-info":[{"award-number":["82001415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202206060005"],"award-info":[{"award-number":["202206060005"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2009403"],"award-info":[{"award-number":["2021YFC2009403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ajp.2022.103267","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:42:06Z","timestamp":1664282526000},"page":"103267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study"],"prefix":"10.1016","volume":"77","author":[{"given":"Nan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihong","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2022.103267_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/ajp.155.7.974","article-title":"Smoking cessation treatment for patients with schizophrenia","volume":"155","author":"Addington","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jop.12495","article-title":"Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: a retrospective cohort study","volume":"46","author":"Ahmadi-Motamayel","year":"2017","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.ajp.2022.103267_bib3","first-page":"228","article-title":"Homozygous deletion of glutathione peroxidase 1 and aldehyde dehydrogenase 1a1 genes is not associated with schizophrenia-like behavior in mice","volume":"1","author":"Bai","year":"2013","journal-title":"J. Biochem Pharm. Res"},{"key":"10.1016\/j.ajp.2022.103267_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.schres.2013.02.001","article-title":"No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia","volume":"146","author":"Ballesteros","year":"2013","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.ajp.2022.103267_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157015911795596595","article-title":"Oxidative stress in schizophrenia","volume":"9","author":"Bo\u0161kovi\u0107","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ajp.2022.103267_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0891-5849(99)00173-2","article-title":"Tissue-specific functions of individual glutathione peroxidases","volume":"27","author":"Brigelius-Floh\u00e9","year":"1999","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.ajp.2022.103267_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1570-0232(02)00618-9","article-title":"Analytical methods to investigate glutathione and related compounds in biological and pathological processes","volume":"781","author":"Camera","year":"2002","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ajp.2022.103267_bib8","first-page":"13","article-title":"Antioxidant properties of second-generation antipsychotics: focus on microglia","author":"Caruso","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ajp.2022.103267_bib9","article-title":"Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review","volume":"153","author":"Cecerska-Hery\u0107","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ajp.2022.103267_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrn2849","article-title":"Nicotine addiction and nicotinic receptors: lessons from genetically modified mice","volume":"11","author":"Changeux","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ajp.2022.103267_bib11","article-title":"Cigarette smoking and schizophrenia: etiology, clinical, pharmacological, and treatment implications","volume":"2021","author":"Ding","year":"2021","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.ajp.2022.103267_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.neubiorev.2009.07.013","article-title":"Smoking, nicotine and neuropsychiatric disorders","volume":"34","author":"Dome","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ajp.2022.103267_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/1098-2396(200010)38:1<10::AID-SYN2>3.0.CO;2-T","article-title":"Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex","volume":"38","author":"Drew","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.ajp.2022.103267_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/ajp.150.4.546","article-title":"Cigarette smoking: implications for psychiatric illness","volume":"150","author":"Glassman","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102932","article-title":"Blood-based oxidation markers in medicated and unmedicated schizophrenia patients: a meta-analysis","volume":"67","author":"Goh","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.ajp.2022.103267_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1748-1716.1986.tb07988.x","article-title":"Nicotinic effects on the firing pattern of midbrain dopamine neurons","volume":"128","author":"Grenhoff","year":"1986","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.ajp.2022.103267_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0197-0186(03)00009-3","article-title":"Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells","volume":"43","author":"Guan","year":"2003","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ajp.2022.103267_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08958370701401418","article-title":"Oxidative stress in smokers and non-smokers","volume":"19","author":"Isik","year":"2007","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.ajp.2022.103267_bib19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/01.CIR.101.19.2252","article-title":"Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease","volume":"101","author":"James","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ajp.2022.103267_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-016-0749-7","article-title":"Oxidative stress in drug-na\u00efve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders","volume":"268","author":"Jordan","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2022.103267_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2022.103267_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.pharmthera.2005.10.015","article-title":"Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy","volume":"111","author":"Kirkham","year":"2006","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.ajp.2022.103267_bib23","first-page":"145","article-title":"Review: Free radicals, antioxidants, and the immune system","volume":"30","author":"Knight","year":"2000","journal-title":"Ann. Clin. Lab Sci."},{"key":"10.1016\/j.ajp.2022.103267_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-021-01036-3","article-title":"Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-Week results from a prospective longitudinal study","author":"Li","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ajp.2022.103267_bib25","doi-asserted-by":"crossref","unstructured":"Liu, H., R. Yu, Y. Gao, X. Li, X. Guan, K. Thomas, M. Xiu and X. Zhang, 2021b. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. Curr Neuropharmacol.","DOI":"10.2174\/1570159X19666210920090547"},{"key":"10.1016\/j.ajp.2022.103267_bib26","doi-asserted-by":"crossref","unstructured":"Liu, H., H. Liu, S. Jiang, L. Su, Y. Lu, Z. Chen, X. Li, X. Li, X. Wang, M. Xiu, X. Zhang, 2021a. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. Curr Neuropharmacol.","DOI":"10.2174\/1570159X19666211111123918"},{"key":"10.1016\/j.ajp.2022.103267_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fpsyt.2018.00672","article-title":"Neurobiological determinants of tobacco smoking in schizophrenia","volume":"9","author":"Lucatch","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib28","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1164\/ajrccm.160.supplement_1.15","article-title":"Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease","volume":"160","author":"Macnee","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ajp.2022.103267_bib29","doi-asserted-by":"crossref","first-page":"303s","DOI":"10.1378\/chest.117.5_suppl_1.303S-a","article-title":"Oxidants\/antioxidants and COPD","volume":"117","author":"MacNee","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ajp.2022.103267_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","article-title":"Pharmacological treatment of negative symptoms in schizophrenia","volume":"265","author":"M\u00f6ller","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2022.103267_bib31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1164\/ajrccm.162.3.2001063","article-title":"Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers","volume":"162","author":"Montuschi","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ajp.2022.103267_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.703452","article-title":"Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders","volume":"12","author":"Murray","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0166-4328(00)00204-7","article-title":"Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness","volume":"113","author":"Nomikos","year":"2000","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.ajp.2022.103267_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-244X-11-124","article-title":"Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients","volume":"11","author":"Raffa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1172\/JCI200421146","article-title":"Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice","volume":"114","author":"Rangasamy","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ajp.2022.103267_bib36","first-page":"216","article-title":"Smoking in schizophrenia: an updated review","volume":"30","author":"\u0160agud","year":"2018","journal-title":"Psychiatr. Danub"},{"key":"10.1016\/j.ajp.2022.103267_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.scr.2013.09.012","article-title":"Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells","volume":"12","author":"Sato","year":"2014","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.ajp.2022.103267_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pnpbp.2012.06.013","article-title":"Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain","volume":"39","author":"Stojkovi\u0107","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.schres.2005.04.016","article-title":"Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect","volume":"79","author":"Williams","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2022.103267_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2013.02.015","article-title":"Free radicals, antioxidant defense systems, and schizophrenia","volume":"46","author":"Wu","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103267_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaa062","article-title":"Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with schizophrenia","author":"Xiu","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2022.103267_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ajp.2022.103267_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.schres.2005.10.011","article-title":"Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics","volume":"81","author":"Zhang","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2022.103267_bib44","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.npp.1301317","article-title":"Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia","volume":"32","author":"Zhang","year":"2007","journal-title":"Neuropsychopharmacology"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:44:13Z","timestamp":1761756253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201822002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":44,"alternative-id":["S1876201822002659"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103267","relation":{},"ISSN":["1876-2018"],"issn-type":[{"type":"print","value":"1876-2018"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smoke, GPx activity and symptoms improvement in patients with drug-naive first-episode schizophrenia: A large-scale 12-week follow-up study","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103267"}}